Is Geron Corporation (GERN) a Buy, Sell, or Hold?
Geron Corporation
NASDAQ:GERN
$1.38 USD
-$0.04 (-2.82%)
- Volume
- 11.74M
- Average Volume
- 14.13M
- Market Capitalization
- $885.3M
- P/E Ratio
- -13.23
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $2.01
- Year Low
- $1.04
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.78
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Harout Semerjian |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GERN |
| CUSIP | 374163103 |
| CIK | 0000886744 |
| Web | https://www.geron.com |
| Phone | 650 473 7700 |
| Currency | USD |
| Employees | 258 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.10 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.78 |
| Quick Ratio | 6.78 |
| Cash Ratio | 0.96 |
Sales & Book Value
| Annual Sales | $183.88M |
| Price / Sales | 4.51 |
| Cash Flow | -0.19 |
| Price / Cash Flow | -7.01 |
| Price / Book | 4.03 |
Price Target and Rating
| Average Stock Price Forecast | $6.00 |
| High Stock Price Forecast | $8.00 |
| Low Stock Price Forecast | $4.00 |
| Forecast Upside/Downside | -77.00% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 22 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.13 |
| Trailing P/E Ratio | -13.23 |
| PEG Ratio | -0.20 |
| P/E Growth | -0.20 |
| Net Income | $-85.78M |
| Net Margin | -35.48% |
| Pretax Margin | -35.48% |
| Return on Equity | -28.90% |
| Return on Assets | -13.03% |
Financials Score
| AltmanZ Score | -2.05 |
| Piotroski Score | 1.00 |
| Working Capital | 424.96M |
| Total Assets | 534.12M |
| Ebit | -37.98M |
| Market Cap | 885.3M |
| Total Liabilities | 305.01M |
Poll Results
About Geron Corporation (NASDAQ:GERN) Stock
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California. ...
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-14 16:26:00
FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 1,700,000 shares of Geron common stock to Chinmaya Rath, Geron's new Chief Business Officer, as an inducement material to his acceptance of employment with Geron.
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
2026-07-13 08:00:00
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies
Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up
2026-07-01 10:11:08
Geron Corporation delivered Q1'26 Rytelo revenues of $51.8M, up 8% sequentially, with two consecutive quarters of demand growth. GERN maintained 2026 guidance, with net product revenues of $220M-$240M expected. Management is now prioritizing high-volume community accounts, aiming to shift sales mix from academic centers to the broader 80% community-driven market.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-18 16:01:00
FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
2026-06-08 11:38:32
Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)
2026-06-04 10:36:21
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-01 08:00:00
FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m.
Geron: Time To Reconsider This Oversold Biotech
2026-06-01 05:53:08
Geron has secured FDA approval for RYTELO in low- to intermediate-1 risk MDS, marking a pivotal milestone after decades of development. Despite disappointing initial RYTELO sales, GERN forecasts 2026 revenues of $220–$240 million and is executing targeted commercial and European expansion strategies. A new management team is in place, with significant liquidity ($341 million) and a cash runway of ~2.7 years supporting ongoing pipeline and commercial efforts.
Frequently Asked Questions
-
What is the current Geron Corporation (GERN) stock price?
-
Geron Corporation(NASDAQ:GERN) stock price is $1.38 in the last trading session. During the trading session, GERN stock reached the peak price of $2.01 while $1.04 was the lowest point it dropped to. The percentage change in GERN stock occurred in the recent session was --2.82% while the dollar amount for the price change in GERN stock was -$-0.04.
-
GERN's industry and sector of operation?
-
The NASDAQ listed GERN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GERN?
-
Joseph Emile Eid | Executive Vice President of Research & Development and Chief Medical Officer
Harout Semerjian | Chief Executive Officer, President & Director
Aron Feingold | Vice President of Investor Relations & Corporate Communications
Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer
Ahmed ElNawawi | Executive Vice President & Chief Commercial Officer -
How many employees does GERN have?
-
Number of GERN employees currently stands at 258. GERN operates from 919 East Hillsdale Boulevard, Foster City, CA 94404, US.
-
Link for GERN official website?
-
Official Website of GERN is: https://www.geron.com
-
How do I contact GERN?
-
GERN could be contacted at phone #650 473 7700 and can also be accessed through its website. GERN operates from 919 East Hillsdale Boulevard, Foster City, CA 94404, US.
-
How many shares of GERN are traded daily?
-
The average number of GERN shares traded daily for last 3 months was 14.13M.
-
What is the market cap of GERN currently?
-
The market value of GERN currently stands at $885.3M with its latest stock price at $1.38